|Bid||750.05 x 800|
|Ask||0.00 x 1000|
|Day's Range||808.89 - 828.12|
|52 Week Range||668.00 - 853.97|
|Beta (5Y Monthly)||0.14|
|PE Ratio (TTM)||23.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
In this piece, we will take a look at JP Morgan’s top 15 stock picks for 2023 and most recent stock picks. If you want to skip our introduction to the world’s biggest bank in terms of assets, its latest performance, and other details, then check out JP Morgan’s Top 5 Stock Picks for 2023. […]
Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.
Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.